Prof. Rafi Carasso warns: "The approach to weight-loss injections is changing"
The doctor and media personality addressed the thriving weight-loss drug industry on his 103FM radio show and presented data from a new clinical trial. Alongside the impressive results, he emphasizes the central problem: "When people stop because of side effects – it is cause for concern."
The weight-loss injection industry has become a massive source of profit for pharmaceutical companies in recent years, but it now appears that the medical community is beginning to view the phenomenon with more caution. During his program on 103FM radio, neurology and pain management expert Prof. Rafi Carasso addressed the shift in medical perception regarding these treatments.
Prof. Carasso shared data from a clinical trial conducted by the pharmaceutical company Eli Lilly for a new drug it developed. The findings showed that within a year and a half, participants managed to reduce about 28% of their body weight — a figure significantly higher compared to existing weight-loss injections on the market, which typically lead to a reduction of 18% to 20%.
However, alongside the high efficacy, Prof. Carasso also presented the complexity associated with the treatment. According to the data, up to 18% of the study group were forced to stop taking the injection due to the side effects they experienced.
The medical expert clarified that for people suffering from dangerous obesity, this is a very effective solution, but he qualified his remarks and emphasized the problematic nature of the phenomenon: "Our approach as doctors to weight-loss injections is changing. Since quite a few people stop the medication because of side effects — this is cause for concern."
